

Table 1. Percentage of clusters of BPSD symptoms, reported besides the NPI during 14 weeks treatment with memantine, for none symptoms, divided into group B (treatment before) and group N (no former treatment)

	WEEK 0	WEEK 2	WEEK 8	WEEK 14
Delusions	12.5	12.7	13.6	16.7
Hallucinations	14.6	10.9	18.2	9.5
Agitation	29.2	14.9	22.7	9.5
Insomnia	16.7	10.6	11.4	11.9
Depression/fear	31.3	21.3	30.0	14.3
Wandering	33.3	19.2	22.7	23.8
None	16.7	29.8	38.6	42.9
* Group B	<i>n</i> = 5	<i>n</i> = 6	<i>n</i> = 6	<i>n</i> = 6
* Group N	<i>n</i> = 3	<i>n</i> = 8	<i>n</i> = 11	<i>n</i> = 12




Fig. 1. Change of mean MMSE from baseline until end of study (week 14) after treatment of 20 mg/day memantine, divided into former treatment and no former treatment for Alzheimer's disease.




Fig. 2. Change of mean NPI from baseline until end of study (week 14) after treatment of 20 mg/day memantine, divided into former treatment and no former treatment for Alzheimer's disease

Table 2. Percentage of adverse events ($N=47$) during 14 weeks treatment of memantine

	WEEK 2	WEEK 8	WEEK 14
Somnolence	6.4	2.2	0
Nausea	4.3	0	7.3
Dizziness	4.3	0	2.4
Other	23.4	24.4	2.4
Total	38.4	26.6	12.1